Non-Small Cell Lung Cancer Treatment Market Share

Geographically, the non-small cell lung cancer treatment market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific industry is anticipated to hold largest revenue share by 2036, owing to increasing diagnosis rates of non-small cell lung cancer, and need to develop innovative treatment solutions in the region.

Furthermore, in 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the growing investment of governmental and non-governmental agencies in lung cancer research, accompanied by the presence of leading healthcare service providers in the region. Along with this, North America also leads in terms of adoption of advanced immunotherapies along with other therapies, which is also expected to contribute to the market growth in the region. Alternatively, the market in Europe is also anticipated to occupy a significant share in the non-small cell lung cancer treatment market on account of its proven success in terms of research & development and a high prevalence of non-small lung cancer in the region. In Europe, lung cancer is the leading cause of cancer-related deaths and about 85% of all lung cancer cases are classified as those of non-small cell lung cancer.